Ethan Murdock, Yeonjung Jo, Zeynep Irem Ozay, Varun Nandakumar, Georges Gebrael, Edwin Lin, Gabriel Hooper, Nicolas Sayegh, Micah Ostrowski, Chadi Hage Chehade, Patrick Campbell, Ayana Srivastava, Rachel Revillo, Roberto H Nussenzveig, Benjamin L. Maughan, Haoran Li, Neeraj Agarwal, Umang Swami. "Treatment (Rx) patterns and outcomes with second-line (2L) therapy in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with cabozantinib plus nivolumab (cabo+nivo) or lenvatinib plus pembrolizumab (len+pem) in first-line (1L).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.442